MainboardGMP
LIVE
LIVE GMP
Kwick Forensic Solutions Ltd₹+64·Lumino Industries Ltd₹+56·Sumax Engineering Ltd₹+25·Annu Projects Ltd₹+6·Skyways Air Services Ltd₹+42·ABH Healthcare Ltd₹0·Madhur Knit Crafts Ltd₹0·Hy-Tech Engineers Ltd₹+42·Symbiotec Pharmalab Ltd.₹+285·Rays of Belief Ltd₹+18·Deepa Jewellers Ltd₹+25·Ashutosh Fibre Ltd₹+25·Shanti Inorganics Ltd₹+31·Purple Style Labs Ltd₹0·Priority Jewels Ltd₹+40·Complete Sports & Management India Ltd₹0·Paluck Technologies Ltd₹+25·ESDS Software Solution Ltd₹+342·Augmont Enterprises Ltd₹+313·Tempsens Instruments (India) Ltd₹+305·Dhanwel Hybrid Seeds Ltd₹0·Gaja Alternative Asset Management Ltd₹+18·Mopshop Distribution Ltd₹0·Sunshine Pictures Ltd₹+80·Shankesh Jewellers Ltd₹+2·Lalithaa Jewellery Mart Ltd₹+40·Horizon Industrial Parks Ltd₹+2·Technocrats Plasma Systems Ltd₹+18·Kwick Forensic Solutions Ltd₹+64·Lumino Industries Ltd₹+56·Sumax Engineering Ltd₹+25·Annu Projects Ltd₹+6·Skyways Air Services Ltd₹+42·ABH Healthcare Ltd₹0·Madhur Knit Crafts Ltd₹0·Hy-Tech Engineers Ltd₹+42·Symbiotec Pharmalab Ltd.₹+285·Rays of Belief Ltd₹+18·Deepa Jewellers Ltd₹+25·Ashutosh Fibre Ltd₹+25·Shanti Inorganics Ltd₹+31·Purple Style Labs Ltd₹0·Priority Jewels Ltd₹+40·Complete Sports & Management India Ltd₹0·Paluck Technologies Ltd₹+25·ESDS Software Solution Ltd₹+342·Augmont Enterprises Ltd₹+313·Tempsens Instruments (India) Ltd₹+305·Dhanwel Hybrid Seeds Ltd₹0·Gaja Alternative Asset Management Ltd₹+18·Mopshop Distribution Ltd₹0·Sunshine Pictures Ltd₹+80·Shankesh Jewellers Ltd₹+2·Lalithaa Jewellery Mart Ltd₹+40·Horizon Industrial Parks Ltd₹+2·Technocrats Plasma Systems Ltd₹+18·
Home IPOs Symbiotec Pharmalab Ltd.
SY
Symbiotec Pharmalab Ltd.
CLOSED NSE & BSE Mainboard Fresh capital cum OFS
GREY MARKET PREMIUM
₹ + 285
+29% expected return
EST. LISTING PRICE
₹1,273
Issue Price: ₹ 988
Issue Price
₹988
Face Value
₹2
Lot Size
15 shares
Open Date
24 Aug 2026
Close Date
27 Aug 2026
Allotment
28 Aug 2026
Listing Date
01 Sep 2026
Exchange
NSE & BSE
About the Company

Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets across regulated and emerging regions.

With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea, and other global regulatory organisations.

As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres.

Symbiotec Pharmalab focuses on research-driven manufacturing, quality compliance, and sustainable production processes. It supports the pharmaceutical, nutraceutical, and wellness industries by providing high-quality ingredients aligned with global standards.

Competitive Strengths:

  • Global leadership in corticosteroid and steroidal hormone APIs.
  • Long-standing relationships with domestic and international customers.
  • Fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a strong regulatory track record.
  • Continuous investment in research and development, supported by strong technological capabilities among Indian industry peers.
  • Ability to leverage its scientific expertise and existing capabilities to expand its total addressable market and develop intellectual property-driven offerings.
Objects of the Issue
Purpose Amount (₹ Cr)
Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company ₹113
General corporate purposes
Lead Managers
JM Financial Ltd Avendus Capital Pvt.Ltd Motilal Oswal Investment Advisors Ltd. Nomura Financial Advisory & Securities (India) Pvt.Ltd.
Financial Summary Amount in ₹ Crore
Metric 31 Mar 2026 31 Mar 2025 31 Mar 2024
Total Assets 1,781 1,580 1,295
Revenue 872 756 723
PAT 110 97 100
EBITDA 232 206 177
Net Worth 1,159 821 721
Reserves 1,146 810 710
Total Borrowing 388 541 247
Key Financial Ratios
ROE
13
ROCE
12
RONW
12
PAT Margin
13
EBITDA Margin
27
P/BV
150
Issue Details
Total Shares Offered
12,460,533
Pre-Issue Shareholding
61,681,496 shares
Post-Issue Shareholding
63,202,757 shares
IPO Analytics Dashboard
LIVE
IPO Insights
📊
Valuation
Moderate
IPO Strength Score
4 / 10 Moderate
0–3 Weak 3–6 Moderate 6–8 Good 8–10 Strong
Category-wise Subscription Shares offered, bid & amount
Category Sub (x) Offered Bid For
🏦 QIB 181.20 3,550,608 643,359,195
💼 NII / HNI 77.56 2,662,955 206,535,120
👤 Retail (RII) 13.69 6,213,562 85,046,805
Σ Total 75.08 12,460,533 935,486,175

* Amount calculated at upper price band (₹988) ·  ** Total includes all investor categories

Application Sizing Minimum investment by category
👤 Retail Investors ?
Min. Lots 1
Shares / Lot 15
Min. Investment 14,820
IPO Timeline & Key Dates
  1. 1 💳 Initiation of Refund 31 Aug 2026
  2. 2 📂 Credit of Shares to Demat 31 Aug 2026
  3. 3 🔒 Lock-in Period (30%) Sun, Sep 27, 2026
  4. 4 🔒 Lock-in Period (50%) Thu, Nov 26, 2026
Investor Interpretation
  • Detailed subscription data will appear once the IPO opens.

This IPO has relatively lower interest or stretched valuation. Proceed with thorough research and caution.

Company Info
📍 385/2, Pigdamber, Rau, Mhow, Indore, Madhya Pradesh, 453331
Visit Website
Registrar
MUFG Intime India Pvt.Ltd
Check Allotment Status
Disclaimer

The information on mainboardgmp.com is provided for educational and informational purposes only.

We are not a Securities and Exchange Board of India (SEBI)-registered investment advisor, analyst, broker, or financial planner. The content, data, and insights on this website, including Grey Market Premium (GMP), subscription data, IPO dates, and market information, are not intended as financial advice or recommendations to buy, sell, or hold securities.

GMP and related IPO data are collected from unofficial market sources and may not reflect actual IPO listing performance or future price movements. You should not rely solely on the information provided here to make financial or investment decisions.

Investing in IPOs and securities involves risk. Always conduct your own research and consult a qualified SEBI-registered financial advisor before making investment decisions. mainboardgmp.com and its owners shall not be liable for any financial losses, trading losses, or damages arising from use of this website.

By using this website, you acknowledge and agree that you use the content at your own risk.